Data from secondary biomarker endpoints of growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels were further supportive of the findings

growth factor Interstitial cystitis/bladder pain syndrome Completed dosing in its Phase I study 5/17/13 Trevi Therapeutics Inc. (New Haven, Conn.) Nalbuphine hydrochloride Extended-release tablets End-stage renal disease Started a Phase I trial 5/7/13 Umecrine Mood AB (Solna, Sweden) UC1010 Inhibits the provocateur to act on the emotional center of the brain Premenstrual dysphoric disorder Began dosing in a Phase I/II trial 5/24/13 Versartis Inc. (Redwood City, Calif.) VRS-317 A long-acting form

growth factor receptor-activating mutations 5/16/13 Jennerex Biotherapeutics Inc. (San Francisco) Pexa-Vec JX-594

growth factor 19 and improvement in clinical symptoms 5/21/13 INFECTION Chimerix Inc. (Durham, N.C.) CMX001 Oral nucleotide analog lipid-conjugate Cytomega-lovirus Data demonstrated its high barrier to viral resistance in the prevention and treatment of the infection 5/17/13 Gilead Sciences Inc. (Foster city, calif.) Sofosbuvir and ledipasvir Once-daily fixed-dose combination tablet Hepatitis C virus Interim Phase II data showed a sustained virologic response four weeks after completing therapy

RXI-109 is a self-delivering RNAi that is designed to reduce expression of a protein known as connective tissue growth factor (CTGF

Both previous tie-ups involve Ambrx's protein medicinal chemistry technology, one targeting fibroblast growth factor 21 for Type II diabetes and the other focused on the relaxin hormone for the treatment of heart failure

That decision was made in the wake of the FDA's Oncology Drugs Advisory Committee (ODAC) 13-1 vote against the adequacy of Aveo Pharmaceuticals Inc.'s tivozanib, an inhibitor of all three vascular endothelial growth factor receptors, in renal cell carcinoma (RCC

In the wake of the FDA's Oncology Drugs Advisory Committee (ODAC) 13-1 vote against the adequacy of AVEO Pharmaceuticals Inc.'s tivozanib, an inhibitor of all three vascular endothelial growth factor (VEGF) receptors, in renal cell carcinoma (RCC) there were several losers: patients, the company and its staff

The authors used gene therapy to deliver two genes for growth factors directly into the brains of transgenic mice that are transgenic for one part of mutant huntingtin and so develop the equivalent of Huntington's disease

RXi Pharmaceuticals Corp., of Westborough, Mass., disclosed the unblinded results of the first of two placebo-controlled double-blind studies in volunteers with anti-scarring agent RXI-109, an sd-rxRNA compound that has been shown in vitro and in animals to reduce mRNA for connective tissue growth factor

Both previous tie-ups involve Ambrx's protein medicinal chemistry technology, one targeting fibroblast growth factor 21 for Type II diabetes and the other focused on the relaxin hormone for the treatment of heart failure

Its product candidates include Vimizim (N-acetylgalactosamine 6-sulfatase), BMN-701 , a fusion protein of insulin-like growth factor 2 and acid alpha glucosidase, for Pompe disease, BMN-673 for genetically defined cancers and BMN-111 for achondroplasia

GM-CSF was first recognized as a growth factor for white blood cells back in the late 1980s, and recombinant GM-CSF has long been used to treat neutropenia in cancer patients

GM-CSF was first recognized as a growth factor for white blood cells back in the late 1980s, and recombinant GM-CSF has long been used to treat neutropenia in cancer patients

AXL kinase is central to the cell-to-cell signal transduction process known as epithelial-mesenchymal transition (EMT), by which cancer cells escape to form metastases and also is involved in the development of resistance to chemotherapeutics, most notably epidermal growth factor receptor (EGFR)-targeted therapies

GM-CSF was first recognized as a growth factor for white blood cells back in the late 1980s, and recombinant GM-CSF has long been used to treat neutropenia in cancer patients

AXL kinase is central to the cell-to-cell signal transduction process known as epithelial-mesenchymal transition (EMT), by which cancer cells escape to form metastases and also is involved in the development of resistance to chemotherapeutics, most notably epidermal growth factor receptor (EGFR) targeted therapies

AbbVie Inc., of Chicago, reported results from a Phase I study of ABT-199, an investigational BCL-2 (B-cell lymphoma 2) selective inhibitor, for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and relapsed/refractory non-Hodgkin's lymphoma (NHL). The Phase I, open-label, multicenter, international trial was designed to assess the safety, determine the maximum tolerated dose and recommended Phase II dose, and evaluate the pharmacokinetics of ABT-199 in

CO-1686, a targeted covalent (irreversible) inhibitor of mutant forms of the epidermal growth factor receptor (EGFR) in patients with initial activating EGFR mutations as well as the dominant resistance mutation T790M, garnered four confirmed partial responses (PRs) in heavily pre-treated patients, and "may not yet even be close to the maximum tolerated dose (MTD)," wrote J.P. Morgan analyst Cory Kasimov in a research report